ClinicalTrials.gg
CompletedNCT03452891Updated Oct 5, 2023Results posted

Effect of Locally-Applied Simvastatin on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients

A Phase 4 interventional study of Methylcellulose and Simvastatin-Methylcellulose in Periodontal Diseases, sponsored by University of Nebraska. Completed at 1 site in United States. Open to participants aged 40 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-05.

Sponsored by University of Nebraska · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Study summary

The purpose of this study is to determine of local application of commericially-available, FDA-approved preparation of simvastatin is effective in increasing clinical attachment levels (primary outcome), as well as alveolar bone (secondary outcome) compared to standard mechanical therapy in patients on periodontal maintenance therapy (PMT). Subjects undergoing PMT at the UNMC College of Dentistry clinics will be recruited to participate in the randomized one-year clinical trial based on the following eligibility criteria: 1) diagnosis of chronic advanced periodontitis (generalized or localized), 2) participating in regular PMT visits (3-6) month intervals), 3) no systemic diseases or medication which significantly impact periodontal inflammation or bone turnover (e.g. steroids, bisphosphonates, > 325 mg aspirin/day and in good general health, 4) one experimental quadrant of the mouth with an inflamed 6-9 mm interproximal posterior periodontal pocket with history of bleeding on probing (BOP), 5) willingness to sign consent form. Subjects will be divided into two groups for additional therapy in a 6-9 mm interproximal periodontal pocket at baseline: 1) local anesthesia and mini-flap reflection with subgingival mechanical debridement plus application of the simvastatin-methylcellulose gel or 2) local anesthesia and mini-flap reflection with subgingival mechanical debridement plus application of methylcellulose gel alone. Samples/measurement will be obtained at the designated experimental site at baseline, 2 weeks, 6 and 12 months during PMT: 1) digital radiographs (baseline and 12 months only; bone height measurements), 2) presence of explorer-detectable supragingival plaque, 3) 30-second gingival crevicular fluid (GCF) sample (markers of inflammation, bone turnover), 4) recession from the cemento-enamel junction, 5) probing pocket depth and bleeding on probing (BOP). Following the 12-month visit, the research-specific intervention and measurements in the experiment quadrant will be removed from routine PMT.

Read the detailed description

Dental records of patients attending routine periodontal maintenance therapy visits at the UNMC College of Dentistry clinics are reviewed as part of the direct supervision by faculty, including investigators involved int his study. Assessment includes review of medical and dental histories and previous oral hygiene and periodontal charting. Subjects who appear to qualify (40-85 years old, diagnosis of advanced chronic adult periodontitis, one quadrant with at least 3 posterior teeth and one 6-9 mm periodontal pocket, no systemic diseases or medications which significantly impact periodontal inflammation and bone turnover) will be informed of the study, given an opportunity to ask questions, and given an informed consent form to take home. Once signed consent is obtained, subjects will be randomized to one of the two groups: 1) SRP + SIM or 2) SRP + methylcellulose.

At the baseline visit, all women subjects will be given a urine pregnancy test. Once the pregnancy test is determined to be negative, the following sequence of procedures will be performed by the faculty investigator (AK, RR, RH): 1) assignment of the experimental site (6-9 mm pocket with previous bleeding on probing); 2) remove supraginigval plaque from the experimental tooth with explorer [record positive sites]; 3) insert paper strip into facial and lingual of experimental site sulcus for 30 seconds for gingival crevicular fluid (GCF) sample, remove and place into sterile vial, and freeze at -80º C for testing inflammation markers; 4) measure recession on experimental teeth and adjacent interproximal tooth at mesial-facial, mid-facial, distal-facial, mesial-lingual, mid-lingual and distal lingual with UNC 15 probe; 5) measure probing pocket depths at same surfaces as recession; 6) record sites that bleed within 30 seconds. After the faculty investigator (primary or secondary investigator) leaves, the participating personnel (LK) will; 7) take a baseline radiograph, administer local anesthesia to the experimental site via local injection, 9) surgical mini-flap reflection localized to the experimental site (papilla reflection), 10) remove most of the remaining interproximal soft tissue to allow access to the root and measure markers of inflammation, 11) scaling/root planing of site to remove supra- and subgingival bacterial plaque and calculus; 12) placement of SIM-methylcellulose gel, 13) repositioning of papilla to initial location and placement of intra-oral cyanoacrylate; 14) finish full-mouth measurement of probing depths and bleeding on probing; 15) perform full-mouth scaling to remove supra- and subgingival bacterial plaque and calculus; 16) review oral hygiene instructions.

It is possible that steps 14, 15 and 16 could be completed prior to steps 1-13 on all teeth except experimental and adjacent teeth due to availability of faculty investigators at the time of the PMT appointment.

It is also possible that steps 1-13 could be completed at a separate appointment.

Subjects will return for postoperative visit in two weeks. Subjects will return for subsequent PMT visits after 3, 6, 9 and 12 months. Steps 14-16 will be completed at each visit as part of routine PMT. At 6 and 12 months, steps 2-6 will also be completed. At 12 months, a radiograph will also be taken.

Dental record data that will be recorded at each visit includes probing depths (PD), recession, bleeding on probing (BOP) and presence of plaque (+/-) at test site and adjacent interproximal sites.

The expected amount of time for the baseline visit in 90-120 minutes. The expected amount of time for subsequent visits in 60-90 minutes.

02

Conditions studied

  • Periodontal Diseases

Browse trials for

03

In context

Periodontal Diseases

867 studies on the registry are indexed under Periodontal Diseases; 189 are open to participants now.

This study's enrollment of 50 is above the median of 45 across 557 interventional studies indexed under Periodontal Diseases.

Browse Periodontal Diseases studies →

Lead sponsor

University of Nebraska is the lead sponsor of 496 studies on the registry; 67 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 53 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age 40-85 years,
  2. diagnosis of chronic advanced adult periodontitis,
  3. one quadrant with at least one 6-9 mm interproximal pocket,
  4. overall good systemic health,
  5. willingness to sign consent form.

Exclusion criteria

Exclusion Criteria:

  1. systemic diseases which significantly impact periodontal inflammation and bone turnover (e.g. rheumatoid arthritis),
  2. taking drugs which significantly impact periodontal inflammation and bone turnover (e.g. chronic use of or non-steroidal anti-inflammatory drug (>325 mg/d), estrogens, bisphosphonates, calcitonin, methotrexate),
  3. surgical periodontal therapy within the past year,
  4. pregnant or breast-feeding females.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Simvastatin Methylcellulose

    simvastatin in methylcellulose gel

    Drug: Simvastatin-Methylcellulose

  • Placebo comparator
    Methylcellulose Gel

    Methylcellulose gel

    Other: Methylcellulose

Interventions

  • OtherMethylcellulose

    Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.

  • Simvastatin-Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.

    Also known as: Simvastatin

06

What researchers measure

Primary outcomes

  1. Change in Clinical Attachment Level (CAL)

    The change in CAL will be measured and calculated by measuring recession and subtracting the periodontal probing depth.

    Time frame: The CAL will be measured at 12-months.

07

Results

Posted Feb 9, 2023

Participant flow

Participant flow — Overall Study
MilestoneSIM-MCLMethylcellulose Gel
Started2525
Subjects enrolled2525
Subjects completing study2525
Completed2525
Not completed00

Outcome measures

PrimaryChange in Clinical Attachment Level (CAL)

The change in CAL will be measured and calculated by measuring recession and subtracting the periodontal probing depth.

Time frame:
The CAL will be measured at 12-months.
Reported as:
Mean · millimeters
Change in Clinical Attachment Level (CAL)
millimetersSIM-MCLMethylcellulose Gel
Change in Clinical Attachment Level (CAL)7.0 ± 0.16.9 ± 0.2

Adverse events

Collected over 1 year, 9 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SIM-MCL0/25 (0%)0/25 (0%)0/25 (0%)
Methylcellulose Gel0/25 (0%)0/25 (0%)0/25 (0%)

Baseline characteristics

Fifty periodontal maintenance subjects with chronic inflammation participated in this study.

Age, Categorical
Age, Categorical(Participants)SIM-MCLMethylcellulose GelTotal
<=18 years000
Between 18 and 65 years172037
>=65 years8513
Sex: Female, Male
Sex: Female, Male(Participants)SIM-MCLMethylcellulose GelTotal
Female182038
Male7512
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)SIM-MCLMethylcellulose GelTotal
Count of participants——0
08

Study locations

1 site
  • University of Nebraska, College of Dentistry
    Lincoln, Nebraska 68583, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Jul 2020, 16 months.

Results were first posted in Feb 2023, 2 years 6 months after primary completion.

Of 24 phase 4 interventional studies under Periodontal Diseases, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's 16 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2018
First posted
Mar 2, 2018
StartActual
Mar 1, 2019
Primary completionActual
Jul 31, 2020
CompletionActual
Dec 31, 2020
Results first posted
Feb 9, 2023
Last update
Oct 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03452891
Responsible party
Sponsor
First posted
Mar 2, 2018
Start date
Mar 1, 2019
Primary completion
Jul 31, 2020
Completion
Dec 31, 2020
Results posted
Feb 9, 2023
Last update
Oct 5, 2023

Study contacts

Amy C Killeen, DDS, MS
principal investigator · University of Nebraska Medical Center College of Dentistry

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Simvastatin

Start the discussion